Pharming Group N.V. (PHGUF)
USD 0.84
(0.0%)
USD 0.84
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.87 Million USD | -129.55% |
| 2022 | 18.23 Million USD | -34.51% |
| 2021 | 27.83 Million EUR | -66.09% |
| 2020 | 82.08 Million EUR | 20.31% |
| 2019 | 68.22 Million EUR | 56.99% |
| 2018 | 43.45 Million EUR | 65.32% |
| 2017 | 26.28 Million EUR | 316.6% |
| 2016 | -12.13 Million EUR | 13.5% |
| 2015 | -14.03 Million EUR | -501.07% |
| 2014 | 3.49 Million EUR | 136.65% |
| 2013 | -9.54 Million EUR | 58.67% |
| 2012 | -23.09 Million EUR | 3.7% |
| 2011 | -23.97 Million EUR | 14.78% |
| 2010 | -28.13 Million EUR | -5962.18% |
| 2009 | 479.97 Thousand USD | 101.17% |
| 2008 | -41.02 Million EUR | -14.27% |
| 2007 | -35.89 Million EUR | -50.83% |
| 2006 | -23.79 Million USD | -8.97% |
| 2005 | -21.84 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 3.37 Million USD | 203.22% |
| 2024 Q2 | -3.97 Million USD | 75.97% |
| 2024 Q1 | -16.55 Million USD | -2789.12% |
| 2023 FY | -5.38 Million USD | -129.55% |
| 2023 Q4 | 615.79 Thousand USD | -67.73% |
| 2023 Q1 | -13.66 Million USD | -34.25% |
| 2023 Q2 | 5.29 Million USD | 138.78% |
| 2023 Q3 | 1.9 Million USD | -63.99% |
| 2022 Q1 | 5.61 Million USD | 318.32% |
| 2022 Q2 | 17.82 Million USD | 217.55% |
| 2022 Q3 | 10.52 Million USD | -40.92% |
| 2022 Q4 | -10.17 Million USD | -196.67% |
| 2022 FY | 18.23 Million USD | -34.51% |
| 2021 Q3 | -2.23 Million EUR | -123.22% |
| 2021 Q2 | 9.61 Million EUR | 63.56% |
| 2021 Q1 | 5.87 Million EUR | -73.33% |
| 2021 Q4 | -2.57 Million EUR | -15.17% |
| 2021 FY | 27.83 Million EUR | -66.09% |
| 2020 FY | 82.08 Million EUR | 20.31% |
| 2020 Q4 | 22.03 Million EUR | -7.04% |
| 2020 Q1 | 21.44 Million EUR | -0.36% |
| 2020 Q2 | 14.89 Million EUR | -30.57% |
| 2020 Q3 | 23.7 Million EUR | 59.2% |
| 2019 Q2 | 14.25 Million EUR | 3.68% |
| 2019 FY | 68.22 Million EUR | 56.99% |
| 2019 Q4 | 21.52 Million EUR | 15.15% |
| 2019 Q3 | 18.69 Million EUR | 31.13% |
| 2019 Q1 | 13.75 Million EUR | 85.31% |
| 2018 Q4 | 7.41 Million EUR | -56.87% |
| 2018 Q2 | 8.71 Million EUR | -13.81% |
| 2018 FY | 43.45 Million EUR | 65.32% |
| 2018 Q3 | 17.2 Million EUR | 97.33% |
| 2018 Q1 | 10.11 Million EUR | -8.22% |
| 2017 Q2 | 704.62 Thousand EUR | -82.97% |
| 2017 Q1 | 4.13 Million EUR | 357.71% |
| 2017 Q3 | 10.03 Million EUR | 1324.39% |
| 2017 FY | 26.28 Million EUR | 316.6% |
| 2017 Q4 | 11.02 Million EUR | 9.82% |
| 2016 Q1 | -3.59 Million EUR | 6.1% |
| 2016 FY | -12.13 Million EUR | 13.5% |
| 2016 Q4 | -1.6 Million EUR | 55.68% |
| 2016 Q3 | -3.62 Million EUR | -9.24% |
| 2016 Q2 | -3.31 Million EUR | 7.7% |
| 2015 Q1 | -3.29 Million EUR | -120.93% |
| 2015 FY | -14.03 Million EUR | -501.07% |
| 2015 Q4 | -3.82 Million EUR | -12.31% |
| 2015 Q3 | -3.4 Million EUR | 2.69% |
| 2015 Q2 | -3.5 Million EUR | -6.12% |
| 2014 Q3 | -4.86 Million EUR | -52.78% |
| 2014 Q4 | 15.75 Million EUR | 423.63% |
| 2014 FY | 3.49 Million EUR | 136.65% |
| 2014 Q1 | -4.2 Million EUR | 8.15% |
| 2014 Q2 | -3.18 Million EUR | 24.19% |
| 2013 Q3 | -3.2 Million EUR | -347.78% |
| 2013 Q4 | -4.57 Million EUR | -42.62% |
| 2013 FY | -9.54 Million EUR | 58.67% |
| 2013 Q1 | -3.05 Million EUR | -427.28% |
| 2013 Q2 | 1.29 Million EUR | 142.43% |
| 2012 Q2 | -10.82 Million EUR | -76.28% |
| 2012 Q3 | -7.05 Million EUR | 34.87% |
| 2012 FY | -23.09 Million EUR | 3.7% |
| 2012 Q4 | 932.83 Thousand EUR | 113.23% |
| 2012 Q1 | -6.14 Million EUR | -31.51% |
| 2011 Q2 | -6.65 Million EUR | -9.73% |
| 2011 Q1 | -6.06 Million EUR | 82.06% |
| 2011 Q3 | -6.58 Million EUR | 0.96% |
| 2011 Q4 | -4.67 Million EUR | 29.12% |
| 2011 FY | -23.97 Million EUR | 14.78% |
| 2010 Q4 | -33.79 Million EUR | -279.29% |
| 2010 Q3 | -8.91 Million EUR | -41.63% |
| 2010 Q2 | -6.29 Million EUR | 0.0% |
| 2010 FY | -28.13 Million EUR | -5962.18% |
| 2010 Q1 | - USD | 100.0% |
| 2009 FY | 479.97 Thousand USD | 101.17% |
| 2009 Q4 | -9.14 Million EUR | 6.54% |
| 2009 Q3 | -9.78 Million EUR | 15.13% |
| 2009 Q1 | -8.56 Million EUR | 0.0% |
| 2009 Q2 | -11.52 Million EUR | -34.56% |
| 2008 FY | -41.02 Million EUR | -14.27% |
| 2007 FY | -35.89 Million EUR | -50.83% |
| 2006 FY | -23.79 Million USD | -8.97% |
| 2005 FY | -21.84 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -3362.954% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -610.32% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2745.057% |
| CytoDyn Inc. | -18.05 Million USD | 72.978% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 91.728% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -674979.758% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -168.65% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 3.27% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -16191.213% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2588.676% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 49.724% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 91.209% |
| SQZ Biotechnologies Company | -75.82 Million USD | 93.565% |
| Resverlogix Corp. | -12.74 Million USD | 61.726% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1152.546% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 150.085% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -98.734% |
| Mesoblast Limited | -84.14 Million USD | 94.201% |
| GB Sciences, Inc. | -1.42 Million USD | -243.507% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -610.32% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 72.659% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -43.306% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 26.601% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -54.013% |
| ContraFect Corporation | -56.88 Million USD | 91.423% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -77.384% |
| BioStem Technologies, Inc. | -7.77 Million USD | 37.273% |
| LadRx Corporation | -3.82 Million USD | -27.616% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 69.253% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -336.063% |
| CSL Limited | 3.7 Billion USD | 100.132% |
| Biomind Labs Inc. | -1 Million USD | -383.313% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -423.905% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.961% |
| Nascent Biotech, Inc. | -2.22 Million USD | -118.826% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.203% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 199.282% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 237.84% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -217.669% |
| Marizyme, Inc. | -34.08 Million USD | 85.685% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 41.562% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -764.06% |
| Zenith Capital Corp. | -8.94 Million USD | 45.437% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -71.182% |
| Halberd Corporation | -75.05 Thousand USD | -6401.724% |
| Genus plc | 6.4 Million USD | 176.243% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -145.638% |
| IMV Inc. | -38.67 Million USD | 87.382% |
| Affymax, Inc. | -15.04 Million USD | 67.569% |
| SYBLEU INC | -149.18 Thousand USD | -3170.91% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -367.389% |
| Enzolytics Inc. | -2.14 Million USD | -127.082% |
| argenx SE | -425.04 Million USD | 98.852% |
| AVAX Technologies, Inc. | 6.69 Million USD | 172.906% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -248.044% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -265.391% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -30.246% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -19286.349% |
| Cell Source, Inc. | -4.32 Million USD | -12.813% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -910.128% |
| Q BioMed Inc. | -3.44 Million USD | -41.616% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -15.127% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -288.499% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -85.709% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -7.131% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 91.124% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -68.188% |
| Rebus Holdings, Inc. | -664 Thousand USD | -634.871% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -395.862% |
| Skye Bioscience, Inc. | -13.67 Million USD | 64.309% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -161.726% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -143.398% |
| ONE Bio Corp. | 13.68 Million USD | 135.665% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -152.485% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -333.773% |
| Agentix Corp. | -1.37 Million USD | -255.715% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -67.139% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -208.958% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -27909.552% |
| Kadimastem Ltd | -3.04 Million USD | -60.498% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1764.371% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1074.438% |
| NovAccess Global Inc. | -2.46 Million USD | -97.812% |
| Itoco Inc. | -919.14 Thousand USD | -430.881% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -2117.188% |
| Qrons Inc. | -643.67 Thousand USD | -658.073% |
| Mobile Lads Corp. | -554.55 Thousand USD | -779.911% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.826% |
| International Stem Cell Corporation | -663 Thousand USD | -635.979% |
| Bioxytran, Inc. | -3.82 Million USD | -27.732% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -9169.65% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -23889.892% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 86.545% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -201.579% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -563.13% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -56.848% |
| Neutra Corp. | -229.48 Thousand USD | -2026.293% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 72.179% |
| PureTech Health plc | -146.19 Million USD | 96.662% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 77.295% |
| IXICO plc | -1.43 Million USD | -239.565% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 48.588% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 95.994% |
| CSL Limited | 3.81 Billion USD | 100.128% |
| Cellectis S.A. | -108.85 Million USD | 95.517% |